###begin article-title 0
Monoamine related functional gene variants and relationships to monoamine metabolite concentrations in CSF of healthy volunteers
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 43 48 <span type="species:ncbi:9606">human</span>
Concentrations of monoamine metabolites in human cerebrospinal fluid (CSF) have been used extensively as indirect estimates of monoamine turnover in the brain. CSF monoamine metabolite concentrations are partly determined by genetic influences.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 95 100 95 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR2C</italic>
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A</italic>
###xml 152 154 152 154 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD4</italic>
###xml 206 209 203 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH</italic>
We investigated possible relationships between DNA polymorphisms in the serotonin 2C receptor (HTR2C), the serotonin 3A receptor (HTR3A), the dopamine D4 receptor (DRD4), and the dopamine beta-hydroxylase (DBH) genes and CSF concentrations of 5-hydroxyindolacetic acid (5-HIAA), homovanillic acid (HVA), and 3-methoxy-4-hydroxyphenylglycol (MHPG) in healthy volunteers (n = 90).
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A </italic>
###xml 76 79 76 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH</italic>
###xml 195 201 195 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR2C </italic>
###xml 227 232 227 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD4 </italic>
The HTR3A 178 C/T variant was associated with 5-HIAA levels (p = 0.02). The DBH-1021 heterozygote genotype was associated with 5-HIAA (p = 0.0005) and HVA (p = 0.009) concentrations. Neither the HTR2C Cys23Ser variant, nor the DRD4 -521 C/T variant were significantly associated with any of the monoamine metabolites.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A </italic>
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH </italic>
The present results suggest that the HTR3A and DBH genes may participate in the regulation of dopamine and serotonin turnover rates in the central nervous system.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 531 532 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 690 691 690 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 342 348 <span type="species:ncbi:9606">humans</span>
###xml 361 366 <span type="species:ncbi:9606">human</span>
###xml 538 552 <span type="species:ncbi:9544">rhesus monkeys</span>
Concentrations of the major serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA), the major dopamine metabolite homovanillic acid (HVA), and the major norepinephrine metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) in lumbar cerebrospinal fluid (CSF) have been used extensively as indirect measures of monoamine turnover in the brain of humans. Studies of human twins indicate that CSF 5-HIAA and HVA levels are under familial influence of both genetic and environmental origin, whereas MHPG is under major genetic influence [1]. In rhesus monkeys significant portions of CSF 5-HIAA, HVA, and MHPG in the central nervous system, have been shown to be determined by genetic mechanisms [2].
###end p 10
###begin p 11
###xml 118 120 118 120 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
###xml 171 172 171 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 280 281 280 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 282 283 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 294 297 294 297 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C </sub>
###xml 303 308 303 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR2C</italic>
###xml 343 344 343 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 350 356 350 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR2C </italic>
###xml 463 464 463 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 588 589 588 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
A number of serotonin receptors mediate the effects of serotonin. Among several functions, the serotonin receptor 5-HT2C, which is densely expressed throughout the brain [3], seems to be directly involved in the regulation of serotonin and norepinephrine activities in the brain [4-6]. The 5-HT2C gene (HTR2C) is localised to chromosome Xq24 [7]. An HTR2C variant giving rise to a Cystein to Serine substitution at position 23 of the protein has been identified [8]. This variant was shown to influence the CSF MHPG concentration in a Finnish sample of predominantly alcoholic offenders [9].
###end p 11
###begin p 12
###xml 83 85 83 85 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 147 149 147 149 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 352 354 352 354 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 478 481 478 481 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3A </sub>
###xml 487 492 487 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A</italic>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 544 550 544 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A </italic>
###xml 846 848 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 856 862 856 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A </italic>
###xml 923 925 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 978 980 978 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 728 733 <span type="species:ncbi:9606">human</span>
###xml 971 976 <span type="species:ncbi:9606">women</span>
In contrast to all other serotonin receptors, which are G protein-coupled, the 5-HT3 receptor is a ligand-gated ion channel [10]. In the brain 5-HT3 receptors are localised in areas including the amygdala, hippocampus, and caudate nucleus. In addition to their effects on serotonin-regulated physiological processes, there are data suggesting that 5-HT3 receptors influence the activity of several other neurotransmitters, including norepinephrine and dopamine [11-13]. The 5-HT3A gene (HTR3A) is localised to chromosome 11q23.1-q23.2 [10]. An HTR3A single nucleotide polymorphism (178 C/T) in the upstream regulatory region was recently discovered to be of putative functional importance, because luciferase reporter assays in human embryonal kidney cells showed a two to three times higher activity of the rare allele compared to the wildtype [14]. This HTR3A variant was reported to be associated with bipolar disorder [14] and the personality trait harm avoidance in women [15].
###end p 12
###begin p 13
###xml 14 16 14 16 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 129 131 129 131 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 213 215 213 215 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 230 234 230 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD4</italic>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 307 312 307 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD4 </italic>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 527 532 527 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD4 </italic>
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 637 639 637 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 640 642 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 665 667 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 668 670 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 740 742 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 743 745 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 74 79 <span type="species:ncbi:9606">human</span>
###xml 489 494 <span type="species:ncbi:9606">human</span>
The dopamine D4 receptor has a predominantly cortical localisation in the human brain [16]. Among several effects, the dopamine D4 receptor seems to modulate dopamine synthesis and turnover [17,18]. The dopamine D4 receptor gene (DRD4) is located to chromosome 11p15.5 [19]. Recently, a putative functional DRD4 upstream region variant (-521C/T) was discovered, where the -521C allele was reported to be 40% less active than -521T allele in a chloramphenicol acetyltransferase assay using human retinoblastoma cells [20]. This DRD4 variant was associated with schizophrenia [20] as well as the personality trait novelty seeking in some [21-24] but not all studies [25-31]. However, meta-analyses suggested association with both conditions [32-34].
###end p 13
###begin p 14
###xml 198 200 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 201 203 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 279 280 267 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 281 283 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 303 306 288 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH</italic>
###xml 339 341 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 356 360 341 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH </italic>
###xml 445 447 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 448 450 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 527 533 509 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR2C </italic>
###xml 543 549 525 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A </italic>
###xml 558 563 540 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD4 </italic>
###xml 576 580 558 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH </italic>
The enzyme dopamine beta-hydroxylase (DbetaH) catalyses the conversion of dopamine to norepinephrine. DbetaH is localised in catecholamine-containing vesicles of noradrenergic and adrenergic cells [35,36]. DbetaH enzyme activity has been shown to be heritable to a great extent [1,37]. The DbetaH gene (DBH) is located on chromosome 9q34 [38]. Recently, a DBH promoter variant (-1021 C/T) was shown to strongly influence plasma DbetaH-activity [39-41], indicating a functional effect. In the present study we have examined the HTR2C Cys23Ser, HTR3A 178 C/T, DRD4 -521 C/T and DBH -1021 C/T variants for possible relationships to concentrations of 5-HIAA, HVA, and MHPG in lumbar CSF from healthy Swedish volunteers.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
###xml 8 13 <span type="species:ncbi:9606">human</span>
Healthy human volunteers
###end title 16
###begin p 17
The study was approved by the Ethics Committee of the Karolinska Hospital, Stockholm. Informed consent of the subjects was obtained after the nature of the procedures had been fully explained.
###end p 17
###begin p 18
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
The characteristics and assessment of the subjects participating in the present study have been described previously [42,43]. Caucasian individuals (n = 90) were recruited predominantly among students or hospital staff. Lumbar puncture (LP) was performed in all subjects. Height was also recorded. Back length, defined as the distance between the external occipital protuberance and the insertion point of the lumbar needle with the subject in the lying position, was measured in 63 subjects. Eight to 19 years later a structured interview was performed by a psychiatrist (EJ) to assess psychiatric morbidity (DSM-III-R; [44]), somatic illness and presence of mental and nervous system disorders among relatives. Subjects completed a questionnaire regarding smoking habits. Hospital records were obtained and examined for diagnosis. Genealogical data for antecedents up to the third degree were obtained from parish registers to assess the origin of the individuals. Subjects who reported any lifetime psychiatric disorder were excluded.
###end p 18
###begin p 19
###xml 27 30 <span type="species:ncbi:9606">men</span>
###xml 38 43 <span type="species:ncbi:9606">women</span>
###xml 611 618 <span type="species:ncbi:4097">tobacco</span>
###xml 663 670 <span type="species:ncbi:4097">tobacco</span>
###xml 757 762 <span type="species:ncbi:9606">women</span>
###xml 891 903 <span type="species:ncbi:9606">participants</span>
Of the 90 subjects 52 were men and 38 women. The age range at the time of the structured interview was 29 to 56, with a mean +/- standard deviation of 40.5 +/- 6.4 years. The mean age +/- standard deviation at LP was 27.4 +/- 5.9 years, age range 18 - 43. Thirty-six were university graduates. Twenty-one subjects had a family history of major mental illness defined as at least one first or second degree relative with schizophrenia, schizoaffective disorder, bipolar disorder, recurrent unipolar disorder, other non-organic psychosis, or who had committed suicide. Of the subjects 54 were or had been regular tobacco users, 25 were non-smokers or had only used tobacco once or a few times in their life, while data were missing for 11 individuals. Of the women, 15 used oral contraceptives at LP, 21 did not, while data were missing for two individuals. Except for oral contraceptives all participants were drug free at LP. Genealogical data implicated that 89.6% and 4.7% of the genes originated in ancestors born in Sweden and Finland, respectively, and the remaining 5.7% were distributed on 8 European countries.
###end p 19
###begin title 20
CSF monoamine metabolite concentrations
###end title 20
###begin p 21
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 499 501 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
All subjects had at least 8 h of bed-rest in the hospital, abstaining from food and smoking. CSF samples were obtained by LP between 8 and 9 a.m. with the subjects in the sitting (n = 41) or recumbent (n = 47) position. Samples of 12.5 ml CSF were drawn according to a standardised sampling procedure [45]. Samples were stored at below -20degreesC and analysed within two months. 5-HIAA, HVA, and MHPG concentrations were measured by mass fragmentography with deuterium labelled internal standards [46].
###end p 21
###begin title 22
Genotype analyses
###end title 22
###begin p 23
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 123 129 123 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR2C </italic>
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 206 212 206 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A </italic>
###xml 221 226 221 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD4 </italic>
###xml 240 244 240 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH </italic>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
Venous blood was taken from all individuals into EDTA-containing tubes. DNA was isolated as previously described [47]. The HTR2C Cys23Ser variant was genotyped in accordance with Lappalainen et al [8]. The HTR3A 178 C/T, DRD4 -521 C/T, and DBH -1021 C/T variants were genotyped as previously described [15,26,48].
###end p 23
###begin title 24
Data analyses
###end title 24
###begin p 25
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 573 575 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 229 234 <span type="species:ncbi:9606">women</span>
One way analysis of variance (ANOVA) was used for comparisons between genotypes and 5-HIAA, HVA, and MHPG concentrations, respectively. To correct monoamine metabolite levels for back length and use of oral contraceptives (among women), suggestive but discussed confounding variables for monoamine metabolite concentrations in lumbar CSF [42,43,49], analysis of covariance (ANCOVA) was used. For those subjects where back length was not available, estimated back length values, based on the relationship between back length and height, was used as previously described [42,43]. Significance level was defined as a p-value lower than 0.05. Power was estimated in accordance with published methods [50,51].
###end p 25
###begin title 26
Results
###end title 26
###begin title 27
Relationships between HTR2C genotypes and CSF monoamine metabolite concentrations
###end title 27
###begin p 28
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR2C </italic>
###xml 290 296 290 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR2C </italic>
###xml 672 673 672 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 61 64 <span type="species:ncbi:9606">men</span>
###xml 127 132 <span type="species:ncbi:9606">women</span>
###xml 378 383 <span type="species:ncbi:9606">women</span>
###xml 652 655 <span type="species:ncbi:9606">men</span>
###xml 659 664 <span type="species:ncbi:9606">women</span>
The HTR2C genotyping was successful in 86 individuals. Among men the allele frequencies were 0.88 (Cys23) and 0.12 (Ser23). In women the allele frequencies were 0.89 (Cys23) and 0.11 (Ser23), distributed on the following genotypes: Cys23Cys (81%), Cys23Ser (16%), and Ser23Ser (3%). As the HTR2C gene is localised on the X chromosome, each gender was analysed separately. Among women, the Ser23Ser and Cys23Ser genotypes were pooled and analysed versus the Cys23Cys genotype, because of the small number of Ser23Ser subjects. There were no significant relationship between genotypes and any of the CSF monoamine metabolite concentrations neither among men or women (table 1).
###end p 28
###begin p 29
###xml 23 26 23 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C </sub>
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR2C</italic>
###xml 104 109 <span type="species:ncbi:9606">human</span>
Serotonin receptor 5-HT2C (HTR2C) genotypes and relationships to monoamine metabolite concentrations in human lumbar cerebrospinal fluid.
###end p 29
###begin p 30
###xml 174 176 174 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 191 193 191 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 210 212 210 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
###xml 275 277 275 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d </sup>
###xml 340 342 340 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e </sup>
###xml 405 407 405 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">f </sup>
5-HIAA = 5-hydroxyindoleacetic acid; HVA = homovanillic acid; MHPG = 3-methoxy-4-hydroxyphenylglycol. Statistical comparisons done on monoamine metabolite residuals correcteda and uncorrectedb for back length. c Cys23Ser and Ser23Ser genotypes were combined in the analyses. d Correction for use of oral contraceptives, F = 0.21, p = 0.65. e Correction for use of oral contraceptives, F = 0.84, p = 0.37. f Correction for use of oral contraceptives, F = 0.22, p = 0.64.
###end p 30
###begin title 31
Relationships between HTR3A genotypes and CSF monoamine metabolite concentrations
###end title 31
###begin p 32
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A </italic>
###xml 369 375 369 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A </italic>
###xml 549 550 549 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 621 627 621 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A </italic>
###xml 761 767 761 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A </italic>
###xml 856 862 856 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A </italic>
###xml 1116 1117 1116 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1178 1184 1178 1184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A </italic>
###xml 1536 1538 1536 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 1736 1737 1736 1737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1792 1798 1792 1798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A </italic>
###xml 1838 1839 1838 1839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 825 830 <span type="species:ncbi:9606">women</span>
The HTR3A 178 C/C genotype was the most frequent (67%), followed by the 178 C/T (30%) and the 178 T/T (3%) genotypes. The allele frequencies were 0.82 (178C) and 0.18 (178T). The 178 T/T and 178 C/T genotypes were pooled in the calculations, because of the small number of subjects carrying the 178 T/T genotype. In the total sample there were associations between the HTR3A variant and 5-HIAA (p = 0.002) and HVA (p = 0.006) concentrations, with higher concentrations of these monoamine metabolites in carriers of the T-containing genotypes (table 2). However, when corrected for back-length the association between the HTR3A variant and lumbar HVA concentrations was reduced to a trend (p = 0.08). In the male sub-sample, no significant relationships between HTR3A variation and 5-HIAA or HVA concentrations emerged. Among women the relationship between HTR3A variation and 5-HIAA concentrations, indicating higher 5-HIAA levels in subjects carrying the 178T allele, was significant both uncorrected (p = 0.004), corrected for back-length (p = 0.006), and corrected for use of oral contraceptives (p = 0.03; table 2). However, in the female sub-sample the association between HTR3A and HVA concentrations was of borderline significance (p = 0.05 uncorrected, p = 0.03 corrected for use of oral contraceptives), but was non-significant after correction for back-length (p = 0.12). Inspection of the CSF levels of the different genotype groups indicated a possible heterosis effect with regard to the CSF 5-HIAA and HVA concentrations [52]. We therefore also performed calculations pooling the homozygotic genotypes. However, the probability levels of significance did not exceed those obtained pooling the T/T and C/T genotypes (table 2). There were no significant relationships between the HTR3A genotype and MHPG concentrations (table 2).
###end p 32
###begin p 33
###xml 23 26 23 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3A </sub>
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A</italic>
###xml 104 109 <span type="species:ncbi:9606">human</span>
Serotonin receptor 5-HT3A (HTR3A) genotypes and relationships to monoamine metabolite concentrations in human lumbar cerebrospinal fluid.
###end p 33
###begin p 34
###xml 174 176 174 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 191 193 191 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 210 212 210 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
###xml 265 267 265 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d </sup>
###xml 330 332 330 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e </sup>
###xml 395 397 395 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink">f </sup>
###xml 677 680 <span type="species:ncbi:9606">Men</span>
###xml 730 733 <span type="species:ncbi:9606">Men</span>
###xml 776 781 <span type="species:ncbi:9606">Women</span>
###xml 925 930 <span type="species:ncbi:9606">Women</span>
5-HIAA = 5-hydroxyindoleacetic acid; HVA = homovanillic acid; MHPG = 3-methoxy-4-hydroxyphenylglycol. Statistical comparisons done on monoamine metabolite residuals correcteda and uncorrectedb for back length. c T/T and C/T genotypes were combined in the analyses. d Correction for use of oral contraceptives, F = 5.56, p = 0.02. e Correction for use of oral contraceptives, F = 1.76, p = 0.19. f Correction for use of oral contraceptives, F = 0.17, p = 0.68. Analysing heterosis, i.e. comparing homo- vs heterozygotes: All subjects 5-HIAA: F = 10.03, p = 0.002 (F = 5.71, p = 0.02 after correction for back length). All subjects HVA: F = 7.13, p = 0.009 (F = 2.28, p = 0.10). Men 5-HIAA: F = 1.96, p = 0.17 (F = 1.00, p = 0.32). Men HVA: 2.33, p = 0.13 (F = 1.40, p = 0.24). Women 5-HIAA: F = 6.73, p = 0.01 (F = 5.65, p = 0.02 and F = 3.76, p = 0.06 corrected for back length and use of oral contraceptives, respectively). Women HVA: F = 2.49, p = 0.12 (F = 1.03, p = 0.32 and F = 0.98, p = 0.33 corrected for back length and use of oral contraceptives, respectively).
###end p 34
###begin title 35
Relationships between DRD4 genotypes and CSF monoamine metabolite concentrations
###end title 35
###begin p 36
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD4 </italic>
###xml 362 367 362 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD4 </italic>
###xml 491 492 491 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 185 190 <span type="species:ncbi:9606">women</span>
###xml 471 474 <span type="species:ncbi:9606">men</span>
###xml 478 483 <span type="species:ncbi:9606">women</span>
The DRD4 -521 C/T genotype was the most frequent (58%), followed by the -521 T/T (28%) and the -521 C/C genotypes (14%). The allele frequencies were 0.57 (-521T) and 0.43 (-521C). When women were analysed separately, the -521 C/C and -521 C/T genotypes were pooled, because of the small number of -521 C/C subjects. There was no significant relationship between DRD4 genotypes and any of the CSF monoamine metabolite concentrations neither in the total sample, nor among men or women (table 3).
###end p 36
###begin p 37
###xml 10 12 10 12 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD4</italic>
###xml 98 103 <span type="species:ncbi:9606">human</span>
Dopamine D4 receptor (DRD4) genotypes and relationships to monoamine metabolite concentrations in human lumbar cerebrospinal fluid.
###end p 37
###begin p 38
###xml 174 176 174 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 191 193 191 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 210 212 210 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
###xml 265 267 265 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d </sup>
###xml 330 332 330 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e </sup>
###xml 395 397 395 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink">f </sup>
5-HIAA = 5-hydroxyindoleacetic acid; HVA = homovanillic acid; MHPG = 3-methoxy-4-hydroxyphenylglycol. Statistical comparisons done on monoamine metabolite residuals correcteda and uncorrectedb for back length. c C/C and C/T genotypes were combined in the analyses. d Correction for use of oral contraceptives, F = 0.38, p = 0.54. e Correction for use of oral contraceptives, F = 0.04, p = 0.84. f Correction for use of oral contraceptives, F = 1.09, p = 0.30.
###end p 38
###begin title 39
Relationships between DBH genotypes and CSF monoamine metabolite concentrations
###end title 39
###begin p 40
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH </italic>
###xml 376 380 376 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH </italic>
###xml 563 564 563 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 708 709 708 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 792 796 792 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH </italic>
###xml 877 878 877 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 1066 1067 1066 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 617 620 <span type="species:ncbi:9606">men</span>
###xml 695 700 <span type="species:ncbi:9606">women</span>
The DBH -1021 C/C genotype was the most frequent (71%), followed by the -1021 C/T (26%) and the -1021 T/T genotypes (3%). The allele frequencies were 0.84 (-1021C) and 0.16 (-1021T). The -1021 T/T and -1021 C/T genotypes were pooled in the calculations, because of the small number of subjects with the -1021 T/T genotype. In the total sample there was an association between DBH genotype and 5-HIAA concentrations (p = 0.01 uncorrected, p = 0.003 when corrected for back-length), with higher 5-HIAA levels in subjects with the -1021T containing genotypes (table 4). This relationship reached significance also among men (p = 0.06 uncorrected, p = 0.04 corrected for back length), but not among women (table 4). In the total sample there was a tendency for association (p = 0.09) between the DBH variant and HVA concentrations, with higher HVA levels in -1021T carriers (table 4). When corrected for back-length the strength of this difference was significant (p = 0.03). Neither in the smaller male or female sub-samples this difference reached significance (table 4).
###end p 40
###begin p 41
###xml 27 30 24 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH</italic>
###xml 102 107 <span type="species:ncbi:9606">human</span>
Dopamine beta-hydroxylase (DBH) genotypes and relationships to monoamine metabolite concentrations in human lumbar cerebrospinal fluid.
###end p 41
###begin p 42
###xml 174 176 174 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 191 193 191 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 210 212 210 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
###xml 265 267 265 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d </sup>
###xml 330 332 330 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e </sup>
###xml 395 397 395 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink">f </sup>
###xml 680 683 <span type="species:ncbi:9606">Men</span>
###xml 735 738 <span type="species:ncbi:9606">Men</span>
###xml 781 786 <span type="species:ncbi:9606">Women</span>
###xml 932 937 <span type="species:ncbi:9606">Women</span>
5-HIAA = 5-hydroxyindoleacetic acid; HVA = homovanillic acid; MHPG = 3-methoxy-4-hydroxyphenylglycol. Statistical comparisons done on monoamine metabolite residuals correcteda and uncorrectedb for back length. c T/T and C/T genotypes were combined in the analyses. d Correction for use of oral contraceptives, F = 0.88, p = 0.36. e Correction for use of oral contraceptives, F = 0.46, p = 0.50. f Correction for use of oral contraceptives, F = 0.003, p = 0.96. Analysing heterosis, i.e. comparing homo- vs heterozygotes: All subjects 5-HIAA: F = 9.56, p = 0.003 (F = 13.07, p = 0.0005 after correction for back length). All subjects HVA: F = 4.43, p = 0.04 (F = 7.24, p = 0.009). Men 5-HIAA: F = 3.85, p = 0.06 (F = 4.6187, p = 0.04). Men HVA: 1.95, p = 0.17 (F = 2.31, p = 0.14). Women 5-HIAA: F = 9.14, p = 0.005 (F = 9.74, p = 0.004 and F = 4.11, p = 0.05 corrected for back length and use of oral contraceptives, respectively). Women HVA: F = 4.43, p = 0.04 (F = 6.42, p = 0.02 and F = 1.81, p = 0.19 corrected for back length and use of oral contraceptives, respectively).
###end p 42
###begin p 43
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 159 163 159 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH </italic>
###xml 278 279 278 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 522 523 522 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 639 643 639 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH </italic>
###xml 688 689 688 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 958 959 958 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 332 335 <span type="species:ncbi:9606">men</span>
###xml 399 404 <span type="species:ncbi:9606">women</span>
###xml 777 782 <span type="species:ncbi:9606">women</span>
We also performed calculations pooling the homozygotic genotypes, i.e. analysing possible heterosis [52]. In the total sample there was an association between DBH heterozygosity and 5-HIAA concentrations (p = 0.003 uncorrected, p = 0.0005 when corrected for back-length) (table 4). This relationship reached significance also among men (p = 0.06 uncorrected, p = 0.04 corrected for back length) and women (p = 0.005 uncorrected, p = 0.02 corrected for back length, p = 0.05 corrected for use of oral contraceptives; table 4). In the total sample there was an association (p = 0.04 uncorrected, p = 0.009 corrected for back-length) between DBH heterozygosity and HVA concentrations (table 4). This association failed to obtain significance in the smaller male sub-sample. Among women there was an association (p = 0.04 uncorrected, p = 0.02 corrected for back-length), which however did not survived correction for use of oral contraceptives (p = 0.18; table 4).
###end p 43
###begin p 44
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH </italic>
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
There were no significant relationships between the DBH genotype and MHPG concentrations (table 4).
###end p 44
###begin p 45
###xml 93 96 <span type="species:ncbi:9606">men</span>
###xml 115 120 <span type="species:ncbi:9606">women</span>
Given alpha = 0.05 the present study had a power of 0.93 - 0.96 (total sample), 0.67 - 0.81 (men), or 0.53 - 0.67 (women) to detect differences of a large effect size (f = 0.40). For differences of a medium effect size (f = 0.25) the power was 0.54 - 0.65 (total sample) or less.
###end p 45
###begin title 46
Discussion
###end title 46
###begin p 47
###xml 119 125 119 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A </italic>
###xml 134 139 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD4 </italic>
###xml 149 153 149 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH </italic>
###xml 333 339 333 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A </italic>
###xml 348 352 348 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH </italic>
###xml 246 251 <span type="species:ncbi:9606">human</span>
The present study is, to our knowledge, the first to investigate three potentially functional candidate gene variants (HTR3A 178 C/T, DRD4 -521 C/T, DBH -1021 C/T) in the context of monoamine metabolite concentrations in cerebrospinal fluid from human healthy volunteers. Association was detected between two of these gene variants (HTR3A 178 C/T, DBH -1021 C/T) and the indirect measures of monoamine activity in the brain.
###end p 47
###begin p 48
###xml 108 114 108 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR2C </italic>
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 321 322 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 937 943 937 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR2C </italic>
###xml 999 1000 999 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1457 1463 1457 1463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR2C </italic>
###xml 153 156 <span type="species:ncbi:9606">men</span>
###xml 350 353 <span type="species:ncbi:9606">men</span>
However, we were not able to replicate the previously reported finding of higher CSF MHPG concentrations in HTR2C Ser23 compared to Cys23 carriers among men [9]. On the contrary, our male sub-sample showed a non-significant relationship in the opposite direction, i.e. higher MHPG concentrations in Cys23 subjects (table 1). When we added another 23 men, excluded from the main analysis because of reported life-time psychiatric disorder, mostly alcohol abuse, depressive or anxiety disorders, this difference reached nominal significance (F = 4.44, d.f. = 71, p = 0.04), a result robust for correction for back-length (p = 0.04) and presence of life-time psychiatric disorder (p = 0.04), respectively (data not shown). Reasons for the different results in the two studies may include the different selection of subjects. The previous study included 73% alcoholic violent offenders and 27% healthy controls of Finnish ethnicity, and the HTR2C genotype effect was most prominent among the offenders [9], whereas the present study only included healthy subjects. The present study may lack power to detect the previous relationship. Alternatively, assuming different relationships between alcoholic violent offenders and healthy controls, the Finnish study may be under-powered concerning control subjects. It is also possible that both results are valid, but the results reflect an association to a linked variant, and that the degree of linkage between the HTR2C Cys23Ser variant and the 'real' functional polymorphism differs between the two populations investigated. There may also be a difference between the two populations with regard to other genes interacting with the present to influence MHPG concentrations. It is also possible that the Finnish, the present or both results have emerged by chance.
###end p 48
###begin p 49
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A </italic>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 243 245 243 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Subjects carrying the rarer HTR3A 178T allele, which has been associated with higher protein expression than the wild-type variant [14], displayed higher lumbar CSF 5-HIAA concentrations. This suggests that a more efficient variant of the 5-HT3 receptor, involved in the regulation of serotonin activities, enhances brain serotonin turnover, giving rise to higher levels of the serotonin degradation product in CSF.
###end p 49
###begin p 50
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD4 </italic>
###xml 189 194 189 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD4 </italic>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 322 327 322 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD4 </italic>
###xml 587 592 587 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD4 </italic>
###xml 742 747 <span type="species:ncbi:9606">human</span>
We were not able to find any significant relationships between DRD4 -521 C/T variation and CSF monoamine metabolite concentrations. This is in accordance with previous studies, analysing a DRD4 exon 3 variable number of tandem repeat variant [42,53]. In the present report there was a trend for an association between the DRD4 -521 C/T genotypes and CSF MHPG concentrations. This may mean that the present study does not have sufficient power to detect such a relationship, or that this trend reflects a tendency to a false positive finding. The results so far obtained suggest that the DRD4 gene does not have a large impact on the monoamine turnover in the brain as reflected by the major degradation products of these compounds in healthy human subjects.
###end p 50
###begin p 51
###xml 243 247 240 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH </italic>
###xml 380 382 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 383 385 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 636 640 633 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH </italic>
###xml 904 908 901 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH </italic>
###xml 1372 1374 1369 1371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 1520 1522 1517 1519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 1681 1683 1678 1680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1684 1686 1681 1683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
One would expect that functional variants of the gene encoding the dopamine beta-hydroxylase would primarily affect the catecholamines, in particular norepinephrine. However, in the present study the strongest relationship emerged between the DBH -1021 C/T variant and CSF 5-HIAA levels. Complex interactions between the noradrenergic and serotonergic systems have been reported [54,55]. Altered noradrenergic activity may alter the firing activity of serotonergic neurons, leaving a possibility for a decreased or increased availability of norepinehprine to be involved in these interactions. One might speculate that a more effective DBH variant, giving rise to an enhanced norepinephrine formation, facilitates noradrenergic activity, which in its turn facilitates serotonergic activity, giving rise to larger amounts of the serotonin degradation product 5-HIAA. There was also an association between DBH -1021 C/T variation and the major dopamine degradation product, indicating higher HVA levels in subjects with a less effective enzyme variant. This is in accordance with the theory that a less effective conversion of dopamine to norepinephrine would lead to higher amounts of dopamine, and in turn to its degradation product HVA. However, the stronger associations between heterozygotic genotypes and 5-HIAA and HVA concentrations, examples of positive heterosis [52], rather indicate a more complex physiology including interactions based on hidden stratification of unknown factors or heterozygotic advantage [52]. In this context, an interaction with e.g. the monoamine oxidase A gene, where more effective variants have been reported to increase 5-HIAA concentrations [43,56], may be a possibility. However, these latter results further complicate the task, as they call into question the use of monoamine metabolites as straightforward, although indirect, measures of brain turnover. This may mean that high levels of 5-HIAA may reflect a more effective degradation process rather than an enhanced overall turnover giving a possibility for reduced serotonin transmission to be associated with high levels of 5-HIAA.
###end p 51
###begin p 52
###xml 248 252 248 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH </italic>
It is possible that the present associations may have emerged by chance. Applying Bonferroni's correction would give a p-value of < 0.0011 (0.05/45) to be considered significant. Only one of the reported relationships, i.e. the association between DBH heterozygosity and CSF 5-HIAA levels, would survive such a correction procedure. On the other hand, although relatively large to constitute a sample of healthy subjects investigated by a demanding procedure, i.e. lumbar puncture, the present sample is small from a statistical point of view. The power of the present study was adequate to detect differences of large, but not medium to small effect sizes. Thus, it cannot be excluded that relationships of smaller magnitudes may have escaped our analysis attempts. Applying strict corrections for multiple testing would make investigations like the present impossible to perform, because a sample big enough to withstand such a correction procedure would probably never be possible to obtain. This is especially true taking the detection of small effects into account.
###end p 52
###begin title 53
Conclusions
###end title 53
###begin p 54
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR3A </italic>
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH </italic>
###xml 222 226 222 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DBH </italic>
###xml 345 351 345 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTR2C </italic>
###xml 446 451 446 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD4 </italic>
###xml 176 181 <span type="species:ncbi:9606">human</span>
###xml 389 392 <span type="species:ncbi:9606">men</span>
If replicated, the present results suggests that the HTR3A and DBH variants participate differentially in the regulation of serotonin turnover in the central nervous system of human subjects. It is also suggested that the DBH variant differentially influence dopamine turnover in the brain. The results give some support for an influence of the HTR2C variant on norepinephrine turnover in men, but do not favour a major differential influence of DRD4 gene activities on monoamine metabolite concentrations in lumbar CSF.
###end p 54
###begin title 55
Competing interests
###end title 55
###begin p 56
None declared.
###end p 56
###begin title 57
Authors' contributions
###end title 57
###begin p 58
EGJ performed the second clinical investigation, the statistical analyses, and drafted the manuscript. JB, JM, RAJ, JS, LW, and RI performed the genotyping. SC, PP, MMN and EE participated in the design and co-ordination of the study. GCS conceived of the study and participated in its design and co-ordination. All authors read and approved the final manuscript.
###end p 58
###begin title 59
Pre-publication history
###end title 59
###begin p 60
The pre-publication history for this paper can be accessed here:
###end p 60
###begin p 61

###end p 61
###begin title 62
Acknowledgements
###end title 62
###begin p 63
This study was supported by grants from the Swedish Research Council (8668, K2004-21X-15078-01A), Deutsche Forschungsgemeinschaft (SFB400, TPA3), the Fund for Scientific Research - Flanders (G.0425.02), the National Institute for Mental Health (44814), Soderstrom-Konigska Foundation, the Lundberg Foundation, the Wallenberg Foundation, and the HUBIN project. We thank Kjerstin Lind and Alexandra Tylec for technical assistance.
###end p 63
###begin article-title 64
Concentrations of monoamine metabolites in the cerebrospinal fluid of twins and unrelated individuals - a genetic study
###end article-title 64
###begin article-title 65
###xml 110 124 <span type="species:ncbi:9544">rhesus monkeys</span>
###xml 126 140 <span type="species:ncbi:9544">Macaca mulatta</span>
Paternal and maternal genetic and environmental contributions to cerebrospinal fluid monoamine metabolites in rhesus monkeys (Macaca mulatta)
###end article-title 65
###begin article-title 66
Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors
###end article-title 66
###begin article-title 67
###xml 73 76 <span type="species:ncbi:10116">rat</span>
Serotonergic modulation of the release of endogenous norepinephrine from rat hypothalamic slices
###end article-title 67
###begin article-title 68
A 5-hydroxytryptamine2 agonist augments gamma-aminobutyric acid and amino acid inputs to noradrenergic locus coeruleus neurons
###end article-title 68
###begin article-title 69
###xml 158 161 <span type="species:ncbi:10116">rat</span>
Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: microdialysis studies in the awake and anaesthetized rat
###end article-title 69
###begin article-title 70
###xml 55 60 <span type="species:ncbi:9606">human</span>
###xml 76 81 <span type="species:ncbi:10090">mouse</span>
Serotonin receptor 1c gene assigned to X chromosome in human (band q24) and mouse (bands D-F4)
###end article-title 70
###begin article-title 71
###xml 82 87 <span type="species:ncbi:9606">human</span>
Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C)
###end article-title 71
###begin article-title 72
HTR2C Cys23Ser polymorphism in relation to CSF monoamine metabolite concentrations and DSM-III-R psychiatric diagnoses
###end article-title 72
###begin article-title 73
###xml 21 26 <span type="species:ncbi:9606">human</span>
Molecular cloning of human 5-hydroxytryptamine3 receptor: heterogeneity in distribution and functionamong species
###end article-title 73
###begin article-title 74
###xml 70 73 <span type="species:ncbi:10116">rat</span>
Modulation of norepinephrine release by serotonergic receptors in the rat hippocampus as measured by in vivo microdialysis
###end article-title 74
###begin article-title 75
Serotonin-facilitated dopamine release in vivo: pharmacological characterization
###end article-title 75
###begin article-title 76
The functional importance of 5-HT3 receptors in the interactions between serotonergic and dopaminergic systems in the CNS
###end article-title 76
###begin article-title 77
Association between the 5' UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder
###end article-title 77
###begin article-title 78
###xml 94 99 <span type="species:ncbi:9606">women</span>
A polymorphism in the serotonin receptor 3A gene (HTR3A) is associated with harm avoidance in women
###end article-title 78
###begin article-title 79
###xml 41 46 <span type="species:ncbi:9606">human</span>
D2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects
###end article-title 79
###begin article-title 80
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine
###end article-title 80
###begin article-title 81
Brain dopamine D(4) receptors: basic and clinical status
###end article-title 81
###begin article-title 82
The D4 dopamine receptor (DRD4) maps to distal 11p close to HRAS
###end article-title 82
###begin article-title 83
A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia
###end article-title 83
###begin article-title 84
###xml 84 89 <span type="species:ncbi:9606">human</span>
Identification of a polymorphism in the promoter region of DRD4 associated with the human novelty seeking personality trait
###end article-title 84
###begin article-title 85
Association between Novelty Seeking and the -521 C/Tpolymorphism in the promoter region of the DRD4 gene
###end article-title 85
###begin article-title 86
DRD4 promoter SNPs and gender effects on Extraversion in African Americans
###end article-title 86
###begin article-title 87
Allelic variants interaction of dopamine receptor D4 polymorphism correlate with personality traits in young Korean female population
###end article-title 87
###begin article-title 88
###xml 68 73 <span type="species:ncbi:9606">human</span>
Association analysis of polymorphisms in the upstream region of the human dopamine D4 receptor gene (DRD4) with schizophrenia and personality traits
###end article-title 88
###begin article-title 89
No association between a promoter dopamine D4 receptor gene variant and schizophrenia
###end article-title 89
###begin article-title 90
No association between dopamine D4 receptor gene variants and Novelty Seeking
###end article-title 90
###begin article-title 91
No association of the -521 C/T polymorphism in the promoter of DRD4 with novelty seeking
###end article-title 91
###begin article-title 92
No association between dopamine D4 receptor gene exon III and-521C/T polymorphism and Novelty Seeking
###end article-title 92
###begin article-title 93
Lack of association between polymorphisms of the dopamine D4 receptor gene and personality
###end article-title 93
###begin article-title 94
Polymorphisms of DRD4 and DRD3 and risk of avoidant and obsessive personality traits and disorders
###end article-title 94
###begin article-title 95
DRD4 and novelty seeking: results of meta-analyses
###end article-title 95
###begin article-title 96
Genetic polymorphisms and personality in healthy adults: a systematic review and meta-analysis
###end article-title 96
###begin article-title 97
Dopamine D4 receptor gene (DRD4) variants and schizophrenia: meta-analyses
###end article-title 97
###begin article-title 98
###xml 79 84 <span type="species:ncbi:9606">human</span>
Immunocytochemical localization of dopamine-beta-hydroxylase in neurons of the human brain stem
###end article-title 98
###begin article-title 99
Distribution of dopamine-beta-hydroxylase activity in subcellular fractions of adrenal medulla
###end article-title 99
###begin article-title 100
###xml 42 48 <span type="species:ncbi:9606">humans</span>
Biochemical genetics of catecholamines in humans
###end article-title 100
###begin article-title 101
###xml 20 25 <span type="species:ncbi:9606">human</span>
Localization of the human dopamine beta hydroxylase (DBH) gene to chromosome 9q34
###end article-title 101
###begin article-title 102
###xml 33 38 <span type="species:ncbi:9606">human</span>
A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: Evidence for a major functional polymorphism at the DBH locus
###end article-title 102
###begin article-title 103
A genotype-controlled analysis of plasma dopamine beta-hydroxylase in healthy and alcoholic subjects: evidence for alcohol-related differences in noradrenergic function
###end article-title 103
###begin article-title 104
The structure of linkage disequilibrium at the DBH locus strongly influences the magnitude of association between diallelic markers and plasma dopamine beta-hydroxylase activity
###end article-title 104
###begin article-title 105
Dopamine-related genes and their relationships to monoamine metabolites in CSF
###end article-title 105
###begin article-title 106
A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers
###end article-title 106
###begin article-title 107
Relationships in healthy volunteers between concentrations of monoamine metabolites in cerebrospinal fluid and family history of psychiatric morbidity
###end article-title 107
###begin article-title 108
Simultaneous determination of the three major monoamine metabolites in brain tissue and body fluids by a mass fragmentographic method
###end article-title 108
###begin article-title 109
Dopamine D2 receptor gene polymorphisms in Scandinavian chronic alcoholics
###end article-title 109
###begin article-title 110
No association between a putative functional promoter variant in the dopamine beta-hydroxylase gene and schizophrenia
###end article-title 110
###begin article-title 111
Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms. Relationships to monoamine metabolite concentrations in CSF of healthy volunteers
###end article-title 111
###begin article-title 112
GPower: a general power analysis program
###end article-title 112
###begin article-title 113
Molecular heterosis: a review
###end article-title 113
###begin article-title 114
DRD4 dopamine receptor genotype and CSF monoamine metabolites in Finnish alcoholics and controls
###end article-title 114
###begin article-title 115
Brain noradrenaline and the mechanisms of action of antidepressant drugs
###end article-title 115
###begin article-title 116
Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response
###end article-title 116
###begin article-title 117
Serotonin-related gene polymorphisms and central nervous system serotonin function
###end article-title 117

